Key result
Ticlopidine is more effective than aspirin for stroke prevention in patients with prior TIA or stroke, though it is associated with severe but reversible neutropenia in almost 1% of patients.
Why the study?
Does ticlopidine reduce the risk of subsequent stroke in patients presenting with a transient ischemic attack or stroke?
Does ticlopidine reduce the risk of subsequent stroke in patients presenting with a transient ischemic attack or stroke?
Ticlopidine is an effective option for primary and secondary stroke prevention, particularly for patients unable to take aspirin.
Answers are grounded in this paper and cite their sources.
Ticlopidine may reduce recurrent stroke risk versus aspirin after TIA or stroke; leaves open net benefit given neutropenia and newer agents.
BACKGROUND: Ticlopidine, an antiplatelet agent with a unique mechanism of action, is now available for clinical use in the United States and Canada. SUMMARY OF COMMENT: Recently two large randomized trials demonstrated that ticlopidine can reduce the risk of subsequent stroke in patients presenting with a transient ischemic attack or stroke. One study found that ticlopidine was more effective than aspirin for stroke prevention; however, it was less well tolerated than aspirin and was associated with severe but reversible neutropenia in almost 1% of patients. CONCLUSIONS: Ticlopidine is effective for both primary and secondary stroke prevention. It has a favorable risk/benefit ratio and is a particularly attractive option for patients who are unable to take aspirin.
No takes yet. Share an insight, caveat, or question.
Gregory W. Albers (1992) conducted a review in Transient ischemic attack or stroke. Ticlopidine vs. Aspirin was evaluated on Subsequent stroke. Ticlopidine is more effective than aspirin for stroke prevention in patients with prior TIA or stroke, though it is associated with severe but reversible neutropenia in almost 1% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: